

**FOLFIRI Regimen + Bevacizumab:**  
**Irinotecan - Fluorouracil –**  
**Leucovorin - Bevacizumab**  
(Part I)

Adult Chemotherapy- Medical Oncology  
Metastatic Colorectal Carcinoma



CC1560 0027 06 2018

Name: \_\_\_\_\_

HCN: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

**Allergies:**

☐ **No Known**

Date: DD/MONTH/YYYY

Planned Administration Date: DD/MONTH/YYYY

Cycle \_\_\_\_\_ of \_\_\_\_\_

**Cycle Duration: 14 days**

Date of previous cycle: DD/MONTH/YYYY

**MAY PROCEED WITH DOSES AS WRITTEN IF:**

- ANC **greater than or equal to**  $1.5 \times 10^9/L$  and platelets **greater than or equal to**  $75 \times 10^9/L$ , BP **less than or equal to** 160/100, otherwise notify Medical Oncologist.
- LFT's and Bilirubin assessed.
- Dipstick Urine or laboratory urinalysis for protein at the beginning of each odd (1, 3, 5) numbered cycle. If results are 2+ or 3+ or greater than or equal to 1 g/L laboratory urinalysis for protein, collect 24 hour urine for total protein within 3 days before the next cycle. If this result is abnormal, dose reductions are required

**PREMEDICATIONS:**

☐ **Ondansetron 16 mg PO**

☐ **Dexamethasone 8 mg PO**

☐ Other: \_\_\_\_\_

Authorized Prescriber: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT; PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION. USER WILL BE SOLELY RESPONSIBLE FOR VERIFYING ITS CURRENCY AND ACCURACY.

**FOLFIRI Regimen + Bevacizumab:  
Irinotecan - Fluorouracil –  
Leucovorin - Bevacizumab  
(Part II)**

Adult Chemotherapy- Medical Oncology  
Metastatic Colorectal Carcinoma



CC1560 0027 06 2018

Name: \_\_\_\_\_

HCN: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Weight: \_\_\_\_\_ kg      Height: \_\_\_\_\_ cm      Body Surface Area (BSA) = \_\_\_\_\_

**CHEMOTHERAPY (FOR HOSPITAL PHARMACY)**

☐ **Irinotecan 180 mg/m<sup>2</sup> X BSA = \_\_\_\_\_ mg IV in 500 mL D5W over 90 minutes on day 1**

☐ Dose modification: **180 mg/m<sup>2</sup> X BSA - \_\_\_\_\_ % = \_\_\_\_\_ mg IV in 500 mL D5W over 90 minutes on day 1**

☐ **Leucovorin 400 mg/m<sup>2</sup> X BSA= \_\_\_\_\_ mg IV in 250 mL D5W over 90 minutes on day 1**

☐ **Fluorouracil 400 mg/m<sup>2</sup> X BSA= \_\_\_\_\_ mg IV push on day 1**

☐ Dose modification: **400 mg/m<sup>2</sup> X BSA - \_\_\_\_\_ % = \_\_\_\_\_ mg IV push on day 1, THEN**

☐ **Fluorouracil 2400 mg/m<sup>2</sup> X BSA= \_\_\_\_\_ mg in D5W by continuous IV over 46 hours**

☐ Dose modification: **2400 mg/m<sup>2</sup> X BSA - \_\_\_\_\_ % = \_\_\_\_\_ mg in D5W by continuous IV over 46 hours**

☐ **Bevacizumab 5 mg/kg X weight (kg) = \_\_\_\_\_ mg IV in 100 mL normal saline over:**

- **10 minutes during Cycle 1;**
- **If tolerated without reaction- 10 minutes all other cycles**

(Prior to and post administration, flush lines with normal saline as Bevacizumab is not compatible with D5W; blood pressure measurement pre and post dose for first 3 cycles; and prior to Bevacizumab for subsequent cycles)

**HYDRATION/SUPPORTIVE CARE**

**Atropine 0.4 mg intravenous prn** for early diarrhea, abdominal cramps, rhinitis, lacrimation, diaphoresis, or flushing.

Authorized Prescriber: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Authorized Prescriber's Signature: \_\_\_\_\_ ID #: \_\_\_\_\_

Nurse's Name: \_\_\_\_\_ Date: DD/MONTH/YYYY Time: \_\_\_\_\_

Nurse's Signature: \_\_\_\_\_

THIS IS A CONTROLLED DOCUMENT; PLEASE ENSURE THAT YOU ARE READING THE MOST RECENT VERSION. USER WILL BE SOLELY RESPONSIBLE FOR VERIFYING ITS CURRENCY AND ACCURACY.